&w=3840&q=100)
What is Creatine, the supplement Patrick Schwarzenegger's character in 'The White Lotus' added to his famous shake?
Creatine is a compound the body makes in the liver, kidneys, and pancreas. We can also get it from animal proteins like red meat, fish and chicken. read more
Creatine has become one of the most talked-about supplements online. It's the same Patrick Schwarzenegger's character in 'The White Lotus' added to his famous shake. Considered to be used for fitness, doctors and medical experts often debate its advantages and side-effects.
Dr Imtiaz Desai, a Sydney, Australia-based exercise physiologist, said, 'If we keep it super simple, the body has three sorts of energy systems.' He added, 'It should enable you to do a few more repetitions at the same weight.' It's mostly considered to be a safe supplement in the longer run.
STORY CONTINUES BELOW THIS AD
What is Creatine?
Creatine is a compound the body makes in the liver, kidneys, and pancreas. It is then stored in our muscles and brains. It is a crucial chemical ingredient in our body. It is a quick fuel for our muscles.
We can also get it from animal proteins like red meat, fish and chicken. It has also been labelled as magic powder. It has been popular among fitness athletes, Olympic players. There are cotton-candy flavoured creatine drinks available. It is now a one billion dollar global market.
Netizens react
One user wrote- 'Creatine is awesome and especially for women in peri menopause and menopause.'
Another said, 'I've been using Creatine for couple of months now. It's amazing. Not just for extra energy at the gym or squash court, but also removed brain fog and hence improved memory as well as got rid of my muscle cramps and aches.'
A third commented- 'If you take such things then put work in gym it will pay off, drink water with creatine.'
And another comment read- 'Doctors aren't dieticians… So there is no logic behind consulting a doctor before consuming protein and creatine. They will just prescribe the brand that paid them bucks. I have seen doctors suggesting shitty protein powder with loaded sugar , fats, and other preservatives. So talk to a certified and experienced dietician not doctors.'
STORY CONTINUES BELOW THIS AD
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Sanofi buys US biopharma group Blueprint in $9.1 billion deal
French pharma group Sanofi has agreed to buy US-based Blueprint Medicines Corporation , a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, the companies said on Monday. Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash, representing an equity value of approximately $9.1 billion. The acquisition "represents a strategic step forward in our rare and immunology portfolios. It enhances our pipeline and accelerates our transformation into the world's leading immunology company," said Sanofi CEO Paul Hudson. The deal will add to Sanofi's portfolio the rare immunology disease drug Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU, and a promising advanced and early-stage immunology pipeline . Blueprint's established presence among allergists, dermatologists, and immunologists is also expected to enhance Sanofi's growing immunology pipeline, the companies said. Live Events Ayvakit/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis, a rare immunology disease, which is characterized by the accumulation and activation of aberrant mast cells in bone marrow, skin, the gastrointestinal tract, and other organs. The acquisition will also bring elenestinib, a next-generation medicine for systemic mastocytosis, as well as BLU-808, a highly selective and potent oral wild-type KIT inhibitor that has the potential to treat a broad range of diseases in immunology. Besides $129.00 per share in cash at the closing of the deal, Blueprint shareholders will also receive one non-tradeable contingent value right (CVR) which will entitle the holder to receive two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. The total equity value of the transaction, including potential CVR payments, represents approximately $9.5 billion on a fully diluted basis. Hudson said the deal complements recent acquisitions of other early-stage medicines that remain Sanofi's main field of interest and added that Sanofi still retains a sizeable capacity for further acquisitions.
Time of India
4 hours ago
- Time of India
UAE Health Ministry ends birth and death certification service: What you need to know
In a sweeping administrative change, the UAE Ministry of Health and Prevention (MoHAP) has officially ended its role in issuing birth and death certificates. These vital registration services are now handled by Emirates Health Services (EHS) in the northern emirates, while Dubai and Abu Dhabi continue under their respective local health authorities. Tired of too many ads? go ad free now The transition was made quietly, with MoHAP removing all related service options from its website and discontinuing its WhatsApp-based application system. Residents are now required to navigate a decentralised process based on their emirate of residence. What Has Changed? MoHAP has withdrawn from issuing birth and death certificates. Emirates Health Services (EHS) is now responsible in Sharjah, Ajman, Umm Al Quwain, Ras Al Khaimah, and Fujairah. Dubai Health Authority (DHA) and Abu Dhabi's Department of Health (DoH) continue to manage services locally. (DHA) and Abu Dhabi's Department of Health (DoH) continue to manage services locally. Certificates issued by EHS, DHA, or DoH are fully equivalent to those formerly issued by MoHAP. BIRTH CERTIFICATES: How It Works Now Who Can Apply? Parents (of any nationality), legal guardians, or authorised delegates. Where to Apply? Via the EHS website (requires UAE Pass) Through the Mabrouk Ma Yak platform (for Emiratis only) At EHS public health centres or hospitals Documents Needed: Valid Emirates ID and passport for both parents Hospital-issued, certified birth notification Electronic civil record Marriage certificate or notarised parentage document For UAE citizens with births abroad: Return tickets ID and passports of both parents Attested marriage certificate For complex cases (e.g., prison births): Court-issued documents Letters from correctional facilities or social services Birth notifications Fees & Turnaround (Converted to INR) Birth Certificate in Arabic: AED 65 (~₹1,470) English Copy (optional): AED 65 (~₹1,470) Time to Issue: 1 working day DEATH CERTIFICATES: Procedure and Conditions Who Can Apply? Immediate family members or legally authorised persons. Where to Apply? Through the EHS online portal At a designated public health centre or hospital Documents Required: Emirates ID or passport of the deceased No Objection Certificate (NOC) from Ministry of Interior Official death report In suspicious or unknown-cause deaths: Forensic report Name consistency across all documents is mandatory International Use: Certificates must be attested by the UAE Ministry of Foreign Affairs and International Cooperation and the embassy of the relevant foreign country. Fees & Timelines (Converted to INR) Death Certificate in Arabic: AED 65 (~₹1,470) English Copy (optional): AED 65 (~₹1,470) Time to Issue: 5 minutes for e-certificates Physical copy available upon in-person visit Service Hours Monday to Thursday: 7:30 AM to 3:30 PM Friday: 7:30 AM to 12:00 PM Why the Change Matters The UAE is continuing its trend of devolving administrative authority to regional bodies, particularly for citizen services. Emirates Health Services already manages most public healthcare in the northern emirates, making it a natural successor to MoHAP in handling life-event documentation. The Bottom Line The next time you need a birth or death certificate in the UAE, MoHAP is no longer your go-to authority. Depending on where you live, you'll be interacting with EHS, DHA, or DoH—with new procedures, slightly altered fees, and a greater push toward digital verification. While the transition might be procedural, it signals a larger shift in how civil documentation is administered across the UAE—more digital, more localised, and firmly tied to regional health systems. (Exchange rate used: 1 AED = ₹22.60)
Mint
4 hours ago
- Mint
KKR, TPG eye Relisys Medical Devices in early-stage buyout talks
MUMBAI : Relisys Medical Devices is in early-stage discussions with global private equity firms KKR and TPG for a potential ₹1,200–1,300 crore investment, with the transaction likely to offer a full or partial exit to existing investor Siguler Guff, two people familiar with the matter told Mint. 'While TPG is evaluating the company to strengthen its portfolio, KKR is in discussions with the medical devices maker to build out its med-tech platform under which it acquired Healthium Medtech last year from Apax Funds," one of the people cited above said. TPG, too, may look at developing a med-tech platform of its own, the person added. A majority of the proceeds from the transaction, if it materialises, will likely be secondary in nature, enabling Siguler Guff to partially or fully exit. A smaller primary infusion may also be included to fund Relisys's expansion plans, said the second person. Both private equity firms are expected to seek a controlling stake in the Hyderabad-based medical devices maker. In secondary deals, existing shareholders sell their stakes to other investors and the company doesn't receive any new capital. Such shares are usually traded at a discount to primary equity. While KKR declined to comment, TPG, Siguler Guff, Healthium, and Relisys did not respond to Mint's mails sent on Sunday. Also read: Zydus bets big on vaccines and medtech In February, VCCircle had reported that o3 Capital, a mid-market investment bank, was advising Relisys in its search for potential buyers. The report also noted that existing investor Siguler Guff was exploring a full or partial exit, alongside the company's founders, in a transaction then estimated to be valued at $50–70 million ( ₹435–610 crore). Company background Founded in 1997 by technocrats and clinicians, Relisys Medical Devices manufactures cardiovascular products like drug-eluting stents, balloon catheters, diagnostic catheters, and transcatheter heart valves. It also acquired Multimedics in 2018 to expand its stent-making capabilities globally. In FY24, the company reported revenue of ₹169.4 crore, up slightly from ₹162.7 crore a year earlier. Net profit rose marginally to ₹36.3 crore, according to data from Tracxn. The bustling deal activity in the sector also underscores the growing investor appetite for med-tech companies in India. Some notable transactions include Meril Life Sciences $210 million funding from Warburg Pincus which also invested about $300 million in Appasamy Associates. SMT raised $150 million from Samara Capital while Translumina raised around $90 million from Everstone Capital. Also read: Health ministry to set up a panel to review medical device-related adverse events Sector outlook India's $12 billion med-tech market is projected to hit $50 billion by 2030, according to EY. Despite $3.8 billion in exports last fiscal, the country is still heavily import-dependent, with imports at $8.2 billion, making up 80–85% of domestic consumption. Growth is expected to be driven by rising income levels, wider insurance coverage, medical tourism, and rapid healthcare infrastructure expansion in Tier 2 and 3 cities. EY noted that global MNCs are increasingly choosing India for R&D, manufacturing, and global capability centers (GCCs)—further strengthening the ecosystem. Also read: India eyes global pharma dominance with a ₹5,000 crore revitalisation plan
